Outlook on Global Myocardial Revascularization, Repair and Regeneration Products and Therapies Sales Market Research Report 2017

ResearchMoz added Latest Research Report titled " Global Myocardial Revascularization, Repair, and Regeneration Products and Therapies Sales Market Report 2017 " to it's Large Report database.

In this report, the global Myocardial Revascularization, Repair, and Regeneration Products and Therapies market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Myocardial Revascularization, Repair, and Regeneration Products and Therapies for these regions, from 2012 to 2022 (forecast), covering
United States
China
Europe
Japan
Southeast Asia
India

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=1018519

Global Myocardial Revascularization, Repair, and Regeneration Products and Therapies market competition by top manufacturers/players, with Myocardial Revascularization, Repair, and Regeneration Products and Therapies sales volume, Price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
Medtronic, Inc.
Covidien
Abbott Laboratories
Advanced Cell Technology, Inc.
Bioheart, Inc.
BIOTRONIK GmbH & Company KG
Boston Scientific Corporation
B. Braun Melsungen AG
Cardica, Inc

Browse more details @ http://www.researchmoz.us/global-myocardial-revascularization-repair-and-regeneration-products-and-therapies-sales-market-report-2017-report.html

Table of Contents

Global Myocardial Revascularization, Repair, and Regeneration Products and Therapies Sales Market Report 2017
1 Myocardial Revascularization, Repair, and Regeneration Products and Therapies Market Overview
1.1 Product Overview and Scope of Myocardial Revascularization, Repair, and Regeneration Products and Therapies
1.2 Classification of Myocardial Revascularization, Repair, and Regeneration Products and Therapies by Product Category
1.2.1 Global Myocardial Revascularization, Repair, and Regeneration Products and Therapies Market Size (Sales) Comparison by Type (2012-2022)
1.2.2 Global Myocardial Revascularization, Repair, and Regeneration Products and Therapies Market Size (Sales) Market Share by Type (Product Category) in 2016
1.2.3 Myocardial Revascularization Technologies
1.2.4 Atherosclerosis Management Technologies
1.2.5 Urrent And Emerging Myocardial Repair/Regeneration Technologies
1.3 Global Myocardial Revascularization, Repair, and Regeneration Products and Therapies Market by Application/End Users
1.3.1 Global Myocardial Revascularization, Repair, and Regeneration Products and Therapies Sales (Volume) and Market Share Comparison by Application (2012-2022)
1.3.2 Hospital
1.3.3 Nursing Center
1.3.4 Other

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

Alzheimers Disease and Associated Indications: Exceptional Level of First-in-Class Innovation and Diverse Range of Therapies in Development

ResearchMoz added Latest Research Report titled " Frontier Pharma: Alzheimers Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression " to it's Large Report database.

Alzheimer’s disease (AD), the most common form of dementia, is a progressive, neurodegenerative and currently incurable disease characterized by loss of memory and other mental abilities. It has a devastating impact on independence and quality of life, with patients requiring full-time care in the later disease stages. In addition to cognitive impairment, AD is associated with behavioral and psychological changes, which often represent the greatest challenges for patients and caregivers.

The prevalence of AD is escalating rapidly, largely owing to aging populations, as advancing age is the most important epidemiological risk factor for the disease. This will amplify the already substantial societal and economic costs of the disease over the coming years. This has led to high levels of R&D investment over the past two decades, but clinical trial failure rates within the indication are extremely high and treatment options remain limited. There are no disease-modifying therapies for AD, and current approaches can only temporarily slow the worsening of symptoms.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=1135804

The report focuses on AD alongside four key associated behavioral and psychological indications: anxiety, depression, psychosis and insomnia. These four conditions are highly prevalent in AD and contribute substantially to the disease burden.

Scope

• Unmet need is extremely high in AD, with behavioral and psychological complications contributing significantly to the disease burden
• What are the most important etiological risk factors and pathophysiological processes implicated in AD?
• What is the current treatment algorithm?
• How common are anxiety, depression, psychosis and insomnia in AD?
• The AD pipeline is large and contains a very high proportion of first-in-class product innovation
• Which molecule types and molecular targets are most prominent across AD and its associated indications?
• What are the connections, in terms of first-in-class innovation, between AD and its associated indications?
• Which first-in-class targets are most promising?
• How does the level of first-in-class innovation differ between products in development for anxiety, depression, psychosis and insomnia?
• How does first-in-class target diversity differ by stage of development and molecular target class?

Browse more details @ http://www.researchmoz.us/frontier-pharma-alzheimers-disease-and-associated-indications-exceptional-level-of-firstinclass-innovation-within-ad-and-diverse-range-of-therapies-in-development-for-disorders-such-as-anxiety-and-depression-report.html

Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4

2 Executive Summary 6
2.1 Limited Treatment Options despite Large Market Opportunity 6
2.2 Exceptionally High Level of First-in-Class Innovation within Alzheimer’s Disease Pipeline 6
2.3 Active Deals Landscape Dominated by GPCR-Targeting Products 6

3 The Case for Innovation 7
3.1 Growing Opportunities for Biologic Products 8
3.2 Diversification of Molecular Targets 8
3.3 Innovative First-in-Class Product Developments Remain Attractive 9
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 9
3.5 Sustained Innovation in Alzheimer’s Disease 10
3.6 GBI Research Report Guidance 10

4 Clinical and Commercial Landscape 12
4.1 Disease Overview 12
4.2 Classification of Dementia and Mild Cognitive Impairment 12
4.3 Symptoms, Disease Staging and Prognosis 13

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

Global Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth

ResearchMoz added Latest Research Report titled " Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth " to it's Large Report database.

GBI Research has released the pharmaceutical report “Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth”. The current market for breast cancer consists of five monoclonal Antibodies (mAbs), three of which are targeted at the Human Epidermal growth factor Receptor 2 (HER-2) protein. Four are aimed at improving overall survival in the metastatic setting, and two of these have also received further approvals in the early setting in order to improve long-term remission rates.

The market is currently led by the HER-2 inhibitor Herceptin, which achieved global sales amounting to $6.2 billion in 2012. Over the forecast period from 2012 to 2019, the two novel HER-2 inhibitors, Kadcyla and Perjeta, are expected to achieve strong market penetration due to their appreciable incremental efficacy benefits. Additionally, the market conditions are currently favorable towards mAbs, with a low rate of price depreciation following patent expiry and a high rate of inflation for specialty pharmaceuticals in the US. As a result of this, and despite the empty Phase III pipeline, GBI Research believes that the global market across the leading eight countries have the potential to grow to a value of $10.6 billion by 2019.

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=178527

Scope

•     An introduction to the treatments available for breast cancer, treatment algorithms and the contexts in which mAbs are clinically relevant to this type of cancer.
•     In-depth analysis of the five mAbs approved for breast cancer, with analysis of their safety, efficacy, treatment patterns and strengths and weaknesses. This includes a heat map comparing the drugs in terms of clinical trial results.
•     A comprehensive review of the pipeline for breast cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline for mAbs is analyzed on the basis of phase distribution, program type and molecular target, as is the entire pipeline for all molecule types.
•     Detailed analysis of pipeline drug clinical trials by trial size, trial duration and program failure rate for each molecule type and mechanism of action. Additionally, a detailed analysis of clinical trial endpoints is provided, detailing their importance in this disease area and their commercial relevance to currently marketed products.
• Multi-scenario forecast data for the market is provided to 2019, which takes into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain.
• Discussion of the drivers and barriers for market growth
• Complete analysis of licensing and co-development deals in this market, by year, value, molecule type, Phase and mechanism of action. Additionally, the international network of licensing deals in breast cancer is mapped out by geography.

Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html

Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Monoclonal Antibodies Market in Breast Cancer to 2019 – Introduction
2.1 Symptoms
2.2 Etiology
2.3 Epidemiology
2.4 Pathophysiology
2.5 Diagnosis
2.6 Prognosis and Disease Staging
2.6.1 Classification
2.7 Treatment Options
2.7.1 Surgery and Radiation Therapy
2.7.2 Chemotherapy
2.7.3 Hormonal Therapies
2.7.4 Targeted Therapies
2.7.5 Resistance to Pharmacological Therapies
2.7.6 Treatment Guidelines
2.7.7 Measuring the Effectiveness of Treatment
2.8 GBI Research Report Guidance

3 Marketed Products
3.1 Herceptin (Trastuzumab) – Hoffmann La Roche
3.2 Avastin (Bevacizumab) – Hoffmann La Roche
3.3 Kadcyla (Trastuzumab Emtansine) – Hoffmann La Roche
3.4 Perjeta (Pertuzumab) – Hoffmann La Roche
3.5 Xgeva (denosumab) – Amgen
3.6 Heat Map for Marketed Products
3.7 Conclusion

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG